These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 15370275)
21. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663 [TBL] [Abstract][Full Text] [Related]
22. High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. Robinson JE; Elliott DH; Martin EA; Micken K; Rosenberg ES Hum Antibodies; 2005; 14(3-4):115-21. PubMed ID: 16720981 [TBL] [Abstract][Full Text] [Related]
23. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253 [TBL] [Abstract][Full Text] [Related]
24. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model. Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508 [TBL] [Abstract][Full Text] [Related]
25. Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression. Streeck H; Schweighardt B; Jessen H; Allgaier RL; Wrin T; Stawiski EW; Jessen AB; Allen TM; Walker BD; Altfeld M AIDS; 2007 Apr; 21(7):889-91. PubMed ID: 17415054 [No Abstract] [Full Text] [Related]
26. [Post infection antiidiotype vaccination against HIV: results of a phase Ia pilot study]. Schedel I; Sutor GC; Jurkiewicz E; Hunsmann G; Lundin K; Hirn M Immun Infekt; 1993 Apr; 21 Suppl 1():49-51. PubMed ID: 8344693 [TBL] [Abstract][Full Text] [Related]
27. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513 [TBL] [Abstract][Full Text] [Related]
28. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080 [TBL] [Abstract][Full Text] [Related]
29. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. Johansson S; Goldenberg DM; Griffiths GL; Wahren B; Hinkula J AIDS; 2006 Oct; 20(15):1911-5. PubMed ID: 16988511 [TBL] [Abstract][Full Text] [Related]
30. Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity. Kim JS; Nag P; Landay AL; Alves M; Cohn MH; Bremer JW; Baum LL FEMS Immunol Med Microbiol; 2006 Nov; 48(2):267-73. PubMed ID: 16978244 [TBL] [Abstract][Full Text] [Related]
32. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Burrer R; Haessig-Einius S; Aubertin AM; Moog C Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596 [TBL] [Abstract][Full Text] [Related]
33. Serum concentration of acute phase protein and lipid profile in HIV-1 seropositive patients and its relationship to the progression of the disease. Ogunro PS; Idogun ES; Ogungbamigbe TO; Ajala MO; Olowu OA Niger Postgrad Med J; 2008 Dec; 15(4):219-24. PubMed ID: 19169337 [TBL] [Abstract][Full Text] [Related]
34. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247. Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978 [TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibody hNM01 in HIV-infected patients: a phase I study. Dezube BJ; Doweiko JP; Proper JA; Conway B; Hwang L; Terada M; Leece BA; Ohno T; Mastico RA J Clin Virol; 2004 Dec; 31 Suppl 1():S45-7. PubMed ID: 15567093 [TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibodies decrease the envelope fluidity of HIV-1. Harada S; Monde K; Tanaka Y; Kimura T; Maeda Y; Yusa K Virology; 2008 Jan; 370(1):142-50. PubMed ID: 17900650 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens. Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590 [TBL] [Abstract][Full Text] [Related]
38. Donating antibodies as a treatment for HIV. TreatmentUpdate; 1998 Jul; 10(5):2-3. PubMed ID: 11365624 [TBL] [Abstract][Full Text] [Related]
39. Anti-idiotypic therapeutic strategies in HIV infection. Wilks D; Dalgleish AG Mol Cell Biol Hum Dis Ser; 1992; 1():283-308. PubMed ID: 1341647 [No Abstract] [Full Text] [Related]
40. Human monoclonal antibodies for passive immunotherapy of HIV-1. Katinger H Antibiot Chemother (1971); 1994; 46():25-37. PubMed ID: 7826037 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]